We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

124 hedge funds and large institutions have $182M invested in Lineage Cell Therapeutics in 2021 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 27 increasing their positions, 39 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

457% more call options, than puts

Call options by funds: $1.61M | Put options by funds: $289K

56% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 16

8% more funds holding

Funds holding: 115 → 124 (+9)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

1.15% less ownership

Funds ownership: 45.28% → 44.13% (-1.2%)

5% less capital invested

Capital invested by funds: $192M → $182M (-$9.95M)

31% less repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 39

Holders
124
Holders Change
+9
Holders Change %
+7.83%
% of All Funds
1.91%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
25
Increased
27
Reduced
39
Closed
16
Calls
$1.61M
Puts
$289K
Net Calls
+$1.32M
Net Calls Change
+$448K

Top Buyers

1
BlackRock
BlackRock
New York
+$3.41M
2
RA
Raffles Associates
New York
+$1.05M
3
Morgan Stanley
Morgan Stanley
New York
+$944K
4
Millennium Management
Millennium Management
New York
+$734K
5
Ameriprise
Ameriprise
Minnesota
+$714K

Top Sellers

1
State Street
State Street
Massachusetts
-$7.92M
2
JP Morgan Chase
JP Morgan Chase
New York
-$2.18M
3
Northern Trust
Northern Trust
Illinois
-$975K
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$913K
5
Rafferty Asset Management
Rafferty Asset Management
New York
-$488K
Name Holding Trade Value Shares
Change 		Change in
Stake
PP
101
Pacifica Partners
Canada
$6K – – –
Osaic Holdings
102
Osaic Holdings
Arizona
$5K -$208 -89 -4%
ODG
103
O'Dell Group
Ohio
$5K – – –
RFA
104
Reilly Financial Advisors
California
$5K – – –
TWA
105
TCI Wealth Advisors
Arizona
$5K +$5K +2,137 New
CWP
106
Concord Wealth Partners
Virginia
$4K – – –
LC
107
Lindbrook Capital
California
$4K +$4.04K +1,725 +5,948%
Fifth Third Bancorp
108
Fifth Third Bancorp
Ohio
$3K – – –
AIC
109
Archer Investment Corporation
Indiana
$2.45K – – –
CAPTRUST Financial Advisors
110
CAPTRUST Financial Advisors
North Carolina
$2K – – –
CA
111
CoreCap Advisors
Michigan
$1K +$5 +2 New
CCM
112
Chilton Capital Management
Texas
$1K +$936 +400 New
BA
113
Bivin & Associates
Oklahoma
$1K +$1.4K +600 New
Manulife (Manufacturers Life Insurance)
114
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$186 +$2.52K +1,077 +1%
Bank of Montreal
115
Bank of Montreal
Ontario, Canada
– -$913K -359,381 Closed
Rafferty Asset Management
116
Rafferty Asset Management
New York
– -$488K -193,756 Closed
LWM
117
Laidlaw Wealth Management
New York
– -$264K -104,841 Closed
TSS
118
Two Sigma Securities
New York
– -$244K -96,762 Closed
WG
119
Winton Group
United Kingdom
– -$158K -62,869 Closed
Thrivent Financial for Lutherans
120
Thrivent Financial for Lutherans
Minnesota
– -$107K -42,533 Closed
SWA
121
Sightline Wealth Advisors
Connecticut
– -$38K -14,958 Closed
Group One Trading
122
Group One Trading
Illinois
– -$32.3K -13,807 Closed
EFM
123
E Fund Management
China
– -$28K -11,095 Closed
IA
124
IFP Advisors
Florida
– -$28K -11,077 Closed
CB
125
Community Bank
New York
– -$1K -508 Closed
2 3 4
5
6

LCTX Hedge Fund Activity: Q4 2021 in Review

124 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q4 2021, worth a combined $182M — down 5.2% from $192M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new LCTX positions and 16 closed out — a net gain of 9 holders — while 27 added to existing stakes and 39 trimmed.

The largest buyer was BlackRock, adding an estimated $3.41M. The largest seller was State Street, cutting an estimated $7.92M.

  • 124 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q4 2021, up from 115 in Q3 2021.
  • Funds reported $182M of Lineage Cell Therapeutics stock for Q4 2021, down 5.2% quarter-over-quarter.
  • 25 funds opened new Lineage Cell Therapeutics positions in Q4 2021 and 16 closed out, a net change of +9 holders.
  • The largest Lineage Cell Therapeutics buyer in Q4 2021 was BlackRock, an estimated $3.41M added.
  • The largest Lineage Cell Therapeutics seller in Q4 2021 was State Street, an estimated $7.92M sold.

Based on aggregated 13F filings for Q4 2021.